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Abstract 
Background: Cocaine-induced psychosis (CIP) is among the most serious adverse effects of 
cocaine. Reduced serum BDNF levels have been reported in schizophrenia and psychosis; 
however, studies assessing the involvement of BDNF in CIP are lacking. 
Methods: Twenty-two cocaine-dependent patients (ages 33.65 ± 6.85) who had never 
experienced psychotic symptoms under the influence of cocaine (non-CIP) and eighteen patients 
(ages 34.18 ± 8.54) with a history of CIP completed a two-week detoxification program in an 
inpatient facility. Two serum samples were collected from each patient at baseline and at the end 
of the protocol. Demographic, consumption and clinical data were recorded for all patients. A 
paired group of healthy controls was also included. 
Results: At the beginning of the detoxification treatment, serum BDNF levels were similar in the 
non-CIP and the CIP groups. During early abstinence, the non-CIP group exhibited a significant 
increase in serum BDNF levels (p=0.030), whereas the CIP group exhibited a decrease in serum 
BDNF levels. Improvements in depression (BDI, p = 0.003) and withdrawal symptoms (CSSA, 
p=0.013) show a significant positive correlation with serum BDNF levels in the non-CIP group, 
whereas no correlation between the same variables was found in the CIP group.  
Conclusions: This study suggests that BDNF plays a role in the transient psychotic symptoms 
associated with cocaine consumption. In the non-CIP group, the increase in serum BDNF 
appears to be driven by the effects of chronic cocaine consumption and withdrawal. In contrast, 
patients with CIP share some of the neurotrophic deficiencies that characterize schizophrenia and 
psychosis.  
Key words: addiction; cocaine; cocaine-induced psychosis; CIP, brain-derived neurotrophic 
factor; BDNF 
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Introduction 
The term “cocaine-induced psychosis” (CIP) has been used to describe transient psychotic 
symptoms, such as paranoia, delusions or hallucinations, that usually resolve with abstinence (1). 
Psychotic symptoms are among the most serious adverse effects of cocaine use because they may 
lead to severe behavioral outcomes such as aggression and agitation and because patients 
experiencing such symptoms may be at a higher risk of developing psychosis (2). Despite the 
morbidity and mortality associated with CIP, risk factors for the trait are still not well known. In 
this context, it may be useful to find biological markers of vulnerability that may assist in the 
identification of those patients who are at risk of developing psychotic disorders and in the 
development of new therapeutic strategies. Psychotic symptoms have also been observed in the 
general population, and a clinical continuum from non-clinical to clinical psychosis has been 
reported (3–5). Among cocaine dependents, more than 50 % of patients report experiencing 
psychotic symptoms (2). Whereas some clinical studies have reported that subjects using higher 
cocaine doses have higher CIP scores (1,6,7), others have found no difference in lifetime cocaine 
abuse between CIP and non-CIP subjects in the month prior to admission (1). Other risk factors 
for psychotic experiences include an early age of onset of cocaine use (6) and being male (7). 
However, not all cocaine users develop psychotic symptoms despite prolonged or heavy 
exposure (2,8,9) and those users who do experience psychotic symptoms may be at a higher risk 
of developing psychosis than cocaine users who do not experience those symptoms (8,10). Early 
identification of patients at risk of developing psychosis may help prevent inappropriate 
diagnosis and treatment and may improve long-term outcome (11–13). 
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Genetic risk factors also appear to be involved in the interindividual variability in the probability 
of experiencing psychotic symptoms. A decrease in the activity of the enzyme dopamine beta-
hydroxylase (DBH), which converts dopamine into adrenaline, has been observed in CIP (14,15). 
Reduced DBH activity has also been observed in individuals who exhibit impulsive and 
aggressive behaviors (16,17), which are also associated with CIP (2). The neurotrophin brain-
derived neurotrophic factor (BDNF), which interacts with the dopaminergic system (18,19) and 
with other neurotransmitters involved in schizophrenia, such as glutamate (20–22), may be a risk 
factor for CIP. Low serum BDNF levels have been reported in schizophrenic patients under 
chronic treatment with antipsychotics (23–27) as well as in drug-naïve schizophrenic patients 
(28,29). Additionally, low serum BDNF levels are associated with cognitive impairment, 
especially immediate memory, in chronic schizophrenic patients (30), and BDNF levels increase 
in stable schizophrenic patients after cognitive training (31). In patients who experienced first-
episode psychosis, low BDNF levels have also been reported (32,33), even in drug-naïve patients 
(34). Postnatal stress appears to mediate the BDNF decrease and its consequences on brain 
structure in these patients (33). Moreover, the most frequently studied single nucleotide 
polymorphism (SNP) of the BDNF gene, the Val66Met SNP (35), is associated with changes in 
intracellular trafficking and secretion of the protein (36) and affects serum BDNF levels (37) and 
hippocampal-dependent learning (38). This polymorphism has also been associated with 
cognitive impairment in schizophrenic patients (30) and with social stress-induced paranoia 
(39,40).  
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The objective of this study is to examine the involvement of BDNF in CIP. We evaluate whether 
serum BDNF levels in abstinent cocaine addicts may be capable of differentiating between 
patients with and without psychotic symptoms during cocaine consumption. We will measure 
serum BDNF levels in cocaine addicts immediately after cocaine consumption and after two 
weeks of withdrawal and compare them to serum BDNF levels in a group of healthy controls. 
 
Materials and Methods 
 
Subjects 
Patients included in this study were selected from a group of participants in an independent 
clinical trial for inpatient cocaine detoxification conducted by the Psychiatry Department of the 
University Hospital Vall d’Hebron  in which pharmacological treatment was effectuated with 
caffeine+Biperiden (Biperiden is an anticholingergic and antiparkinsonian agent), 
caffeine+placebo or placebo+placebo (ClinicalTrials.gov Identifier: NCT00495092). All patients 
were cocaine dependent according to the DSM-IV (41) criteria. Exclusion criteria included the 
following factors: 1) lifetime history of psychotic, bipolar, or substance abuse disorder except 
nicotine; 2) current history of mood, psychotic or anxiety disorder; 3) neurological illness; 4) 
history of cranial trauma; 5) being treated with psychotropic medication (antidepressants or 
antipsychotics) at least one month before joining the study; 6) being seropositive for HIV; 7) 
abnormal results on laboratory screening tests or physical examination; 8) having metabolic, 
cardiac or any medical illness that can interfere with the expression of BDNF; 9) being treated 
with chronic drug therapy using corticosteroids, thyroid hormones, allergy medication and/or 
analgesics.  
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Clinical diagnosis was performed by two independent and trained psychiatrists. Sixty-two 
cocaine-dependent patients were assessed for eligibility; of these, 40 met the diagnostic criteria 
for inclusion. A subgroup of 22 patients reported never having experienced psychotic symptoms 
while under the influence of cocaine throughout their lives, whereas a subgroup of 18 patients 
had experienced psychotic symptoms while using cocaine (Figure 1). A gender- and age-
matched sample of 46 healthy controls met the same inclusion criteria. All participants were 
Caucasian and unrelated to one another. 
 
This study was approved by the Clinical Research Ethics Committee of the University Hospital 
Vall d’Hebron. Written informed consent was obtained from all participants Subjects did not 
receive any financial compensation. 
Figure 1. Flow Diagram of the study. 
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Inpatient Procedure 
Patients included in this study underwent a 12-day detoxification treatment in an inpatient unit of 
the Department of Psychiatry, University Hospital Vall d’Hebron. This unit is a locked facility 
where patients have limited visitation privileges and no access to alcohol or drugs. During 
detoxification treatment, drug testing was conducted twice to ensure abstinence. A maximum of 
six breaks per day previously established by the medical team were allowed for smoking. 
 
As part of the independent clinical study, patients received caffeine (starting dosage of 300 mg/d; 
dosage was increased by 300 mg/d; maximum dosage was 15 mg/kg/d up to 1200 mg/d) and 
Biperiden (4 to 8 mg/day) or matched placebo. Caffeine was administered to improve patients’ 
comfort, and Biperiden was administered to prevent tolerance to caffeine. No additional 
psychotropic medication was administered except Lorazepam (up to 5 mg/d) for the treatment of 
insomnia.  
 
Clinical Assessment 
Diagnoses and cocaine dependence were evaluated using the Structured Clinical Interview for 
DSM-IV (SCID) Axis I (42) and Axis II (43). To assess psychotic symptoms under the influence 
of cocaine throughout their life, a structured interview was conducted.  The questions used in 
previous studies (2) and based in DSM IV-TR, were as follows: 1) Have you ever heard, or 
thought you heard, something that wasn’t really there?  Did it happen while you were under the 
effects of cocaine?  2) Have you ever seen, or thought you saw something, that wasn’t actually 
there? Did it happen under the effects of cocaine? 3) Have you ever felt anything unusual on 
your body or on your skin?  Did it happen while you were under the effects of cocaine? 4) Have 
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you believed that people were spying on you, or that someone was plotting against you, or trying 
to hurt you? Did it happen while you were under the effects of cocaine? Patients were considered 
CIP positive by the psychiatrist if they were marked positively in any of the above questions. 
 
Variables related to cocaine consumption, craving and abstinence were systematically registered. 
The Visual Analog Scale (VAS) Craving for cocaine scale (44), the Cocaine Craving 
Questionnaire (CCQ)  (45) and the Cocaine Selective Severity Assessment (CSSA) (46) were 
utilized. Anxiety and depression were evaluated using the State-Trait Anxiety Inventory (47) and 
the Beck Depression Inventory (48), respectively. 
 
Blood sample collection 
For serum sampling, 8 ml of blood was collected from the antecubital vein in anticoagulant-free 
tubes and kept at 4ºC for 2 h. All samples were collected between 10 and 12 h to avoid circadian 
variations. The samples were refrigerated at 4ºC for 2 h and then centrifuged at 3500 rpm for 10 
min at 4ºC. We carefully collected the serum and stored it at -80ºC until performing the BDNF 
assay. 
 
Measurement of serum BDNF 
Levels of human BDNF in serum samples were measured using the Aushon SearchLight 
Multiplex Array (Aushon BioSystems, Billerica, MA), a sandwich enzyme-linked 
immunosorbent system for quantitative protein measurement. In this assay, samples and 
standards were added to wells, and proteins within the samples bound to capture antibodies. The 
integrated values of known standards were used to generate standard curves. We analyzed each 
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sample twice and used the mean of the two BDNF measurements. All mean intra-assay 
coefficients of variation were less than 20%.   
 
Statistical analyses 
Due to the low n in the three subsamples (controls, non-psychotic and psychotic), non-parametric 
statistics were used for all bivariate analyses. Categorical variables were compared between 
groups using chi-squared tests for independence. Continuous variables were compared using the 
Kruskal–Wallis one-way analysis of variance by ranks when comparing the three groups and the 
Mann–Whitney–Wilcoxon rank-sum test when comparing only the non-psychotic and psychotic 
subsamples. Pre and post detoxification BDNF serum levels were compared using the Wilcoxon 
signed-rank test for related samples. Correlations between psychometric scales and BDNF levels 
were performed using Spearman's rank correlation coefficient. Finally, for the variables with 
statistically significant correlations with changes in BDNF levels, a linear regression was used to 
assess if this change could predict symptomatology amelioration. 
 
Results 
Sociodemographic features of patients and control groups 
Table 1 shows comparisons between the control, non-psychotic and psychotic subsamples. No 
gender or age differences were found among groups. As can be seen in Table 2, there were no 
baseline clinical differences between psychotic and non-psychotic patients beyond a small trend 
(z=-1.743, p=.081) on the scale of loss of control from cocaine withdrawal, as evaluated using 
the CCQ. Differences were neither found between treatment groups (caffeine, caffeine-biperiden 
or placebo) in any of these measures. 
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Table 1. Sociodemographic features by patients (with or without psychosis) and control groups. 
 PATIENTS  CONTROLS  Significance  
 
No psychotic 
symptoms (n=22) 
Psychotic symptoms 
(n=18) (n=46)    
Age M SD M SD M SD χ² p 
 33.77  6.98 34.00  8.32 35.52 9.37 1.302 .521 
 N % N % N %   
Gender (% 
female) 2 9.1 1 5.6 5 10.9 *  
 *No statistical test was performed due to low n in the female subsample. 
 
Table 2. Clinical information of patients. Includes consumption data, craving, depression and 
anxiety measures at detoxification treatment baseline. VAS: Visual Analogic Scale Craving for 
cocaine; CCQ: Cocaine Craving Questionnaire; CSSA: Cocaine Selective Severity Assessment; 
BDI: Beck Depression Inventory; STAI: State Trait Anxiety Inventory. 
 
 Non psychotic 
symptoms 
Psychotic symptoms   
Consumption variables Me
an 
SD Mean SD Z P 
Age of onset 24,
05 
13.65 23.38 8.54 -.492 .639 
Days of consumption in the last month 13,
00 
7.55 19.06 9.13 -.560 .585 
Consumption episodes in the last month 21,
14 
2.48 2.77 2.39 -.907 .404 
Maximum quantity in 24 hours in the last 
month (g) 
3,6
7 
4.13 5.90 1.26 -
1.506 
.137 
Baseline addiction measures       
VAS (1-10) 3,1
4 
3.33 2.78 2.81 -.224 .827 
CCQ   25.92 10.19 -
1.003 
.323 
 Desire 22,
00 
10.61 26.00 11.31 -.418 .698 
 Intention 23,
63 
9.23 23.00 11.27 -.326 .767 
 Anticipation 21,
19 
9.77 20.33 8.27 -.372 .732 
 Relief 21,
44 
7.79 55.42 35.42 -
1.743 
.082 
 Loss of control 42,
88 
17.03 17.67 10.59 -.953 .347 
CSSA (18 symptoms) 13,
21 
9.56 2.78 2.81 -.224 .827 
Baseline clinical measures       
BDI. (cut-off for moderate 
depression=7) 
12,
61 
9.33 17.00 8.11 -
1.344 
.183 
STAI. trait (Q3=28) 27.
88 
9.39 31.42 12.72 -.976 .347 
STAI. state (Q3=25) 24.
94 
10.50 29.92 8.56 -
1.115 
.280 
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 Baseline clinical characteristics by patient groups 
 
Table 3 and Figure 2 show the evolution of BDNF serum levels in the two patient groups (CIP 
and non-CIP). There was a clear baseline difference between both treatment groups and the 
control group (total χ²=15.835, p<.0001). There was a clear difference in the evolution of BDNF 
in both groups, but the pre-post difference was only statistically significant for the non-psychotic 
patient group (z=2.025, p=.43). 
 
Table 3. Means (M) and standard deviations (SD) of Brain Derived Neurotrophic Factor 
(BDNF) among healthy controls and cocaine addicted patients with and without psychotic 
symptoms.  
 
   PATIENTS    CONTROLS    
 
  
No psychotic 
symptoms 
(n=23) 
Psychotic 
symptoms 
(n=17) 
Significance 
between 
patients with 
and without 
psychotic 
sypmtoms* 
(n=46)  
Total 
significance** 
   M SD M SD Z p M SD χ² p 
BDNF pre   51.676 17.505 53.947 25.098 -.041 .978 76.044 32.661 15.420 <.0001 
BDNF post 
detoxification 
  
60.643 22.607 48.134 20.376 -1,69 .095     
Significance*** 
  z=-
2.173 
p=.030 
z=-
1.086 
p=.278       
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Figure 2. Boxplot of serum BDNF levels. Se- rum BDNF levels (ng/ml median) repre- sented in 
order from left to right for: (1) the control group, (2) nonpsychotic patients at baseline, (3) 
nonpsychotic patients after 12 days of early detoxification treatment, (4) psychotic group of 
patients at baseline and (5) psychotic group of patients after 12 days of early detoxification 
treatment. Statistically significant differences in se- rum BDNF levels between groups are re- 
ported in table 3 . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Brain-derived neurotrophic factor evolution  
Regarding the evolution of clinical characteristics no differences between patients with or 
without psychotic symptoms in clinical variables were found at the end of the detoxification 
process. As can be seen in table 4, both groups experienced a statistically significant 
improvement in all measures, except for relief from cocaine withdrawal, as evaluated using the 
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CCQ. No differences in BDNF parameters were found between treatment groups (caffeine, 
caffeine-biperiden or placebo). 
 
Correlation of BDNF with symptom improvement during early abstinence 
When the entire sample was taken, the evolution of BDNF levels did not correlate with the 
progression of symptoms. However, when stratifying the two patient groups, there were 
differences in evolution such that changes in BDNF levels were correlated with depression and 
abstinence in the non-psychotic group, whereas there was no correlation in patients who have 
experienced some type of psychotic symptoms 
 
The change in serum BDNF levels was found to be a good predictor of depression (β=.690, 
p<.005; 44.1% of variance explained) but not abstinence, as measured by the CSSA among the 
non-psychotic patients; however, no predictive power of BDNF change was found for any 
variable among psychotic patients. 
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Table 4. Mean, standard deviations, statistical signification and non-parametric correlations with BDNF change of symptom 
improvement in patients with and without psychotic symptoms. Por coherencia conceptual, el cambio en BDNF se ha calculado 
teniendo en cuenta  
 
 
 Symptoms change in non psychotic patients Symptoms change in psychotic patients 
 Mean SD Change 
signification 
Correlation 
with BDNF 
change 
Mean SD Change 
signification 
Correlation 
with BDNF 
change 
   t p ρ p   t p ρ p 
VAS 2.25 2.79 -2.703 .007 .444 .111 2.56 2.14 -2.499 .012 .319 .339 
CCQ             
Desire 8.00 10.63 -2.123 .034 .330 .322 11.55 9.50 -2.625 .009 -.005 .989 
Intention 8.08 10.07 -2.277 .023 .483 .132 13.36 9.48 -2.803 .005 -.373 .259 
Anticipation 7.42 12.59 -1.887 .059 .036 .915 6.73 10.50 -1.886 .059 .209 .537 
Relief 5.25 10.57 -1.845 .065 -.173 .612 4.27 9.39 -1.336 .181 .132 .699 
Loss of control 9.17 11.87 -2.237 .025 .300 .370 22.91 36.70 -2.848 .004 -.301 .368 
CSSA 9.18 9.50 -2.490 .013 .657 .039 13.55 10.23 -2.936 .003 -.187 .582 
Baseline clinical measures             
BDI 8.31 7.03 -2.945 .003 .683 .014 10.50 9.17 -2.449 .014 -.365 .300 
STAI, state 13.36 8.09 -2.847 .004 .236 .511 14.55 8.45 -2.803 .005 -.136 .689 
 
VAS: Visual Analogic Scale Craving for cocaine; CCQ: Cocaine Craving Questionnaire; CSSA: Cocaine Selective Severity Assessment; BDI: Beck Depression 
Inventory; STAI: State Trait Anxiety Inventory. 
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Discussion 
 
To our knowledge, this is the first study to assess the evolution of serum BDNF levels during 
early abstinence in patients with cocaine-induced psychosis (CIP) compared with patients 
without cocaine-induced psychosis (non-CIP).  
 
In this study comparing the CIP and non-CIP groups during early abstinence, both groups 
exhibited different serum BDNF response patterns. At the beginning of detoxification treatment, 
serum BDNF levels were similar in the CIP and the non-CIP groups of patients, but after 12 days 
of withdrawal, BDNF levels were higher in the non-CIP group than in the CIP group. That is, 
whereas the group of patients with no history of psychotic symptoms experienced a significant 
increase in serum BDNF levels, those patients with a history of psychotic symptoms experienced 
a decrease although it was not statistically significant, in BDNF levels. On the other hand, when 
compared to healthy controls, serum BDNF levels in the entire group of cocaine addicts were 
significantly lower both at the beginning and after 12 days of abstinence. The neurobiological 
significance of the decrease of serum BDNF levels in early abstinent cocaine addicts compared 
to healthy controls is discussed in more detail in a previous study (49).  
 
The increase in serum BDNF levels during withdrawal in the non-CIP group of patients is 
consistent with previous studies. In animal models of addiction, it has been extensively 
demonstrated that after cocaine withdrawal BDNF levels rise significantly and progressively in 
different brain regions such as the nucleus accumbens, amygdala and prefrontal cortex (50–52). 
In human addicts, higher serum BDNF levels have been reported after three weeks of abstinence 
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relative to healthy controls (53). The only study that provides data on the evolution of serum 
BDNF during the first weeks of cocaine detoxification was carried out by our group in which we 
found an increase in serum levels of BDNF during the first two weeks of withdrawal (49). BDNF 
is a neurotrophin (54) widely expressed in the adult mammalian brain and is a key factor in 
neuronal survival and neural plasticity in response to environmental stimuli and cognitive 
stimulation (55–57). BDNF also plays a role in cocaine-induced neuroplasticity in different brain 
regions, such as the prefrontal cortex, amygdala, striatum and ventral tegmental area (for a 
review of this topic, see (58). The reported increase of BDNF during cocaine withdrawal may 
mediate neuroplastic changes in brain regions that underlie enhanced responsiveness to cocaine-
related cues and drug seeking in cocaine trained rats (50–52).  
  
In contrast, in the CIP group, BDNF level showed a trend towards a decrease during early 
abstinence. This decrease occurs even though patients received caffeine, a stimulant drug, which 
has been reported to increase BDNF in rats (59) and in sleep-deprived rats (60). This response of 
BDNF in the CIP compared to the non-CIP group suggests the involvement of some additional 
factors that might mask the increase of BDNF during early abstinence. In this regard, reduced 
serum BDNF levels have been reported in schizophrenic patients (23–27,61) and in first-episode 
psychosis (32–34). Additionally, the most frequent single nucleotide polymorphism (SNP) of the 
BDNF gene, the Val66Met SNP (35), is associated with changes in intracellular trafficking and 
secretion of the protein (36) and affects serum BDNF levels (Lang et al., 2009) and 
hippocampal-dependent learning (38). This polymorphism has also been associated with 
cognitive impairment in schizophrenic patients (30) and with social stress-induced paranoia 
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(39,40). Together, these data suggest that patients with psychotic symptoms associated with 
cocaine consumption share some of the BDNF deficiencies that characterize psychosis 
 
There is experimental evidence that BDNF crosses the blood-brain barrier in both directions 
(62,63) and serum or plasma BDNF may reflect brain BDNF levels (64–66) even in 
schizophrenic patients (67). In this context, the low serum BDNF levels found in the CIP group 
reported in the present study may reflect BDNF deficiencies in the brain. Throughout life, BDNF 
is involved in survival and repair in the central nervous system (68) and in long-term activity-
dependent neuroplastic changes (69,70) that underlie normal learning and memory (71). Hence, 
lower than normal levels of BDNF would have profound consequences on the structure and 
function of the prefrontal cortex and other regions of the brain (72,73). Additionally, BDNF also 
mediates another form of activity-dependent plasticity that facilitates the maintenance of some 
degree of constancy and stability within neural networks. This process is known as homeostatic 
plasticity, and it contributes to the attenuation of neuronal excitability and activity, thereby 
allowing the neural network to restore its stability (74–76). For example, BDNF scales the 
quantal amplitude of excitatory synaptic inputs in cortical pyramidal neurons. This scaling 
stabilizes firing rates during periods of intense change in neural activity, thereby contributing to 
synaptic refinement and the regulation of cortical excitability (77,78). BDNF is synthesized and 
released in response to afferent activity (79,80), and dopaminergic, glutamatergic and 
serotoninergic activity considerably change during cocaine consumption and withdrawal (81). 
We hypothesize that the transient psychotic symptoms associated to CIP might be reflecting 
plasticity deficits associated to homeostatic plasticity. Longitudinal studies are necessary to 
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assess whether low serum BDNF levels normalize with abstinence in the CIP group or whether 
BDNF deficiencies persist over time. 
 
The possible role of social and clinical risk factors over the response of BDNF during abstinence 
was also analyzed. There were no significant differences between the CIP and non-CIP groups in 
consumption variables, such as age of first cocaine use, days of consumption per month, or 
maximum quantity of cocaine consumed in 24 hours in the last month before treatment. When 
considering clinical data, patients in the CIP and non-CIP groups exhibited no differences in 
craving, withdrawal symptoms, anxiety or depression, both at the beginning and after 12 days of 
detoxification. During inpatient period, the only drug treatment was caffeine with or without 
biperidene or placebo and there were no difference in BDNF levels between treatment groups. 
All patients received the same diet, performed the same physical exercise, and shared the same 
environmental conditions. Therefore, these data indicate that social and clinical risk factors do 
not explain the differences in the evolution of BDNF levels between the CIP and non-CIP 
groups.  
 
The analysis of the correlation between the evolution of clinical symptoms and serum BDNF 
levels during detoxification treatment also shows differences between CIP and non-CIP patients. 
In the non-CIP group, there was a positive correlation between the improvement of depressive 
and withdrawal symptoms associated with withdrawal and the increase in BDNF levels during 
withdrawal which was not seen in the CIP group. Cocaine withdrawal characterizes by 
symptoms of depression (82) associated to a decreased functionality of the dopaminergic and 
serotoninergic system (83) that resemble those symptoms and deficits that characterizes major 
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depression (84). Depressive disorders also characterize by a decrease of serum BDNF (85–87) 
that recovers with the improvement of clinical symptoms (88). These data suggest that changes 
in serum BDNF in the non-CIP group are driven by neurobiological consequences of repeated 
cocaine consumption and withdrawal. In contrast, in the CIP group no correlation was found 
between scores of depressive and withdrawal symptoms and serum BDNF levels. This contrast 
suggests the possibility of a different neurobiological background underlying the response of 
BDNF during early withdrawal that might result in vulnerability to develop psychotic symptoms 
associated with drug of abuse. 
 
We are aware of the limitations of this study especially related with the limited number of 
patients included in the protocol. In this regard, it is important to mention the difficulty of 
recruiting patients for various reasons. First, patients addicted to cocaine usually have additional 
organic or psychiatric comorbidities and are also subject of poly drug abuse. Both factors were 
exclusion criteria of the study. Additionally, patients pre-recruited in our study were reluctant to 
enter an inpatient regime with very restricted admission conditions. 
 
In summary, these data suggest a different evolution of serum BDNF during early abstinence 
depending on the fact of having had transient psychotic symptoms associated to cocaine 
consumption or not. The increase in serum BDNF in the non-CIP group appears to be driven by 
the effects of chronic cocaine consumption and withdrawal. In contrast, in the CIP group there 
was a trend towards a decrease of serum BDNF during withdrawal suggesting that these patients 
share some of the neurotrophic deficiencies that characterize schizophrenia and psychosis. 
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Therapeutic strategies that tend to activate and stabilize BDNF levels may have a beneficial 
effect in the treatment of CIP and in preventing its transition to psychosis. 
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